Glenmede Trust’s Arcellx ACLX Stock Holding History

Glenmede Trust’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,615	Closed	-$302K	–	1386
2024 Q3	$302K	Buy	+3,615	New	+$241K	﹤0.01%	1090

Other funds holding ACLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's ACLX Position: Q4 2024 in Review

Glenmede Trust sold out of Arcellx (ACLX) in Q4 2024, closing a stake of 3,615 shares — an estimated $302K sold.

Glenmede Trust first reported a position in ACLX in Q3 2024 and held it in 1 quarter. The position peaked at $302K in Q3 2024. 211 funds tracked by Wall St. Rank hold ACLX as of Q4 2024.

Glenmede Trust reported no remaining Arcellx position as of Q4 2024 after selling out during the quarter.
Glenmede Trust sold 3,615 Arcellx shares in Q4 2024, an estimated $302K.
Glenmede Trust first reported a position in Arcellx in Q3 2024 and held it in 1 quarter.
Glenmede Trust's Arcellx position peaked at $302K in Q3 2024.
211 funds tracked by Wall St. Rank held Arcellx as of Q4 2024.

Based on Glenmede Trust's 13F filing for Q4 2024, filed 14 Feb 2025.